Reshma Shringarpure

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341
    Dharminder Chauhan
    Department of Medical Oncology, Harvard Medical School, The Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Oncogene 23:3597-602. 2004
  2. ncbi request reprint Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome
    Reshma Shringarpure
    Ethel Percy Andrus Gerontology Center and Division of Molecular and Computational Biology, University of Southern California, Los Angeles, California 90089 0191, USA
    J Biol Chem 278:311-8. 2003
  3. ncbi request reprint Ezrin turnover and cell shape changes catalyzed by proteasome in oxidatively stressed cells
    Tilman Grune
    Ethel Percy Andrus Gerontology Center and Division of Molecular and Computational Biology, The University of Southern California, Los Angeles, California 90089 0191, USA
    FASEB J 16:1602-10. 2002
  4. ncbi request reprint Preferential degradation of oxidized proteins by the 20S proteasome may be inhibited in aging and in inflammatory neuromuscular diseases
    Kelvin J A Davies
    The Ethel Percy Andrus Gerontology Center, Division of Molecular and Computational Biology, University of Southern California, Los Angeles, CA, USA
    Neurology 66:S93-6. 2006
  5. ncbi request reprint Protein turnover by the proteasome in aging and disease
    Reshma Shringarpure
    Ethel Percy Andrus Gerontology Center and the Division of Molecular and Computational Biology, The University of Southern California, Los Angeles, CA 90089 0191, USA
    Free Radic Biol Med 32:1084-9. 2002
  6. pmc Antimyeloma activity of heat shock protein-90 inhibition
    Constantine S Mitsiades
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston MA 02115, USA
    Blood 107:1092-100. 2006
  7. ncbi request reprint Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma
    Laurence Catley
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA
    Cancer Res 64:8746-53. 2004
  8. ncbi request reprint Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Cell 5:221-30. 2004
  9. pmc Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 101:540-5. 2004
  10. ncbi request reprint Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival
    Renate Burger
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 123:869-78. 2003

Detail Information

Publications22

  1. ncbi request reprint Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341
    Dharminder Chauhan
    Department of Medical Oncology, Harvard Medical School, The Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    Oncogene 23:3597-602. 2004
    ....
  2. ncbi request reprint Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome
    Reshma Shringarpure
    Ethel Percy Andrus Gerontology Center and Division of Molecular and Computational Biology, University of Southern California, Los Angeles, California 90089 0191, USA
    J Biol Chem 278:311-8. 2003
    ....
  3. ncbi request reprint Ezrin turnover and cell shape changes catalyzed by proteasome in oxidatively stressed cells
    Tilman Grune
    Ethel Percy Andrus Gerontology Center and Division of Molecular and Computational Biology, The University of Southern California, Los Angeles, California 90089 0191, USA
    FASEB J 16:1602-10. 2002
    ..Our results indicate that all these oxidant-induced changes may actually be catalyzed by the proteasome...
  4. ncbi request reprint Preferential degradation of oxidized proteins by the 20S proteasome may be inhibited in aging and in inflammatory neuromuscular diseases
    Kelvin J A Davies
    The Ethel Percy Andrus Gerontology Center, Division of Molecular and Computational Biology, University of Southern California, Los Angeles, CA, USA
    Neurology 66:S93-6. 2006
    ....
  5. ncbi request reprint Protein turnover by the proteasome in aging and disease
    Reshma Shringarpure
    Ethel Percy Andrus Gerontology Center and the Division of Molecular and Computational Biology, The University of Southern California, Los Angeles, CA 90089 0191, USA
    Free Radic Biol Med 32:1084-9. 2002
    ....
  6. pmc Antimyeloma activity of heat shock protein-90 inhibition
    Constantine S Mitsiades
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston MA 02115, USA
    Blood 107:1092-100. 2006
    ....
  7. ncbi request reprint Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma
    Laurence Catley
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02215, USA
    Cancer Res 64:8746-53. 2004
    ..These findings have clinical significance, because identification of downstream apoptotic signaling after topoisomerase I inhibition will both elucidate mechanisms of resistance and optimize future combination chemotherapy against MM...
  8. ncbi request reprint Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
    Constantine S Mitsiades
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer Cell 5:221-30. 2004
    ....
  9. pmc Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications
    Constantine S Mitsiades
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 101:540-5. 2004
    ..These findings highlight the pleiotropic antitumor effects of HDAC inhibition, and provide the framework for future clinical applications of SAHA to improve patient outcome in MM...
  10. ncbi request reprint Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival
    Renate Burger
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 123:869-78. 2003
    ..In conclusion, BSF-3 is a novel myeloma growth and survival factor with a potential role in the pathophysiology of the disease...
  11. ncbi request reprint NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma
    Laurence Catley
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    Blood 102:2615-22. 2003
    ..Finally, a study using NVP-LAQ824 in a preclinical murine myeloma model provides in vivo relevance to our in vitro studies. Taken together, these findings provide the framework for NVP-LAQ824 as a novel therapeutic in MM...
  12. ncbi request reprint Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance
    Dharminder Chauhan
    Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Blood 102:3379-86. 2003
    ..Moreover, AS-Hsp27 overcomes interleukin-6 (IL-6)-mediated protection against Dex-induced apoptosis. These data demonstrate that Hsp27 inhibits the release of Smac, and thereby confers Dex resistance in MM cells...
  13. ncbi request reprint Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells
    Mikael Altun
    Department of Pathology, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 65:7896-901. 2005
    ..These data suggest that PS-341 targets both normal and immunoproteasome species to a similar extent in myeloma cells...
  14. ncbi request reprint Oxidized and ubiquitinated proteins may predict recovery of postischemic cardiac function: essential role of the proteasome
    Saul R Powell
    Department of Medicine, Long Island Jewish Medical Center Campus of the Albert Einstein College of Medicine, New Hyde Park, NY 11042, USA
    Antioxid Redox Signal 7:538-46. 2005
    ....
  15. ncbi request reprint Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib
    Klaus Podar
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Res 64:7500-6. 2004
    ....
  16. ncbi request reprint Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells
    Pierfrancesco Tassone
    Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    Blood 104:3688-96. 2004
    ....
  17. ncbi request reprint The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance
    Dharminder Chauhan
    Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Blood 103:3158-66. 2004
    ..Together, these findings provide the framework for clinical evaluation of CDDO-Im, either alone or in combination with bortezomib, to overcome drug resistance and improve patient outcome in MM...
  18. ncbi request reprint Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling
    Yu Tzu Tai
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 63:5850-8. 2003
    ..Moreover, they define the functional association of IGF-IR and beta1 integrin in mediating MM cell homing, providing the preclinical rationale for novel treatment strategies targeting IGF-I/IGF-IR in MM...
  19. ncbi request reprint Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells
    Dharminder Chauhan
    The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Res 63:6174-7. 2003
    ..These findings provide the first evidence that Hsp27 confers PS-341 resistance...
  20. ncbi request reprint GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment
    Klaus Podar
    Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Boston, MA 02115, USA
    Blood 103:3474-9. 2004
    ....
  21. ncbi request reprint Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib
    Reshma Shringarpure
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Br J Haematol 134:145-56. 2006
    ....
  22. ncbi request reprint Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
    Richard LeBlanc
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Blood 103:1787-90. 2004
    ....